This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Liu, P. P Articles by Velazquez, E. J Search for Related Content PubMed PubMed Citation Articles by Liu, P. P Articles by Velazquez, E. J Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Attack Heart Failure Social Bookmarking                         What's this?

Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients

University Health Network in Toronto, University of Toronto, Toronto, Canada, peter.liu{at}utoronto.ca

Aldo Maggioni

ANMCO Research Center, Florence, Italy

Eric J Velazquez

Duke University Medical Center, Durham, NC, USA

Left ventricular (LV) dysfunction and/or heart failure (HF) are frequent complications of hypertension and myocardial infarction (MI), placing affected patients at increased risk of significant morbidity and premature death. Given that the renin-angiotensin-aldosterone system (RAAS) is activated and of pathophysiological importance in such patients, a strong therapeutic rationale exists to target the main effector mechanism (that is, angiotensin II [Ang II]) in order to lessen the associated morbidity and mortality burden.

Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce mortality and LV dysfunction and to slow disease progression in patients with HF, including high-risk, post-MI patients. However, ACE inhibitors (ACE-Is) may not provide optimal long-term RAAS blockade (a finding that is associated with a worse prognosis) such and many patients are unable to tolerate such therapy (because of troublesome dry cough, for example). In contrast, Ang II receptor blockers (ARBs) may block the RAAS more completely than ACE-Is and appear to be better tolerated. Several large-scale trials have evaluated the efficacy of ARBs in patients with LV dysfunction and/or HF (including high-risk, post-MI patients), and have confirmed their utility as an R efficacious and well-tolerated alternative to ACE-Is in this setting.

Key Words: Valsartan • Hypertension • Heart failure • VALIANT trial • Val-HeFT trial

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 1 suppl, S19-S22 (2006)
DOI: 10.3317/jraas.2006.019


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?